1-10 of 10
Shinji Takeuchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Free
Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino, Yuichiro Ohe, Koichi Goto, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1410–1420.
https://doi.org/10.1158/1078-0432.CCR-20-2853
Published: 01 March 2021
View articletitled, Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Open the PDF for Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression in another window
Includes: Supplementary data
Journal Articles

Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention

Free
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nisiyama, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B02.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B02
Published: 01 September 2018
View articletitled, Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention
Journal Articles

Abstract A36: Establishment of patient-derived xenograft models of lung adenocarcinoma with two different EGFR mutations, L858R and exon19 deletion

Free
Kenji Kita, Koji Fukuda, Akihiro Nishiyama, Sachiko Arai, Shinji Takeuchi, Koushiro Ohtsubo, Kaname Yamashita, Masaya Tamura, Isao Matsumoto, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): A36.
https://doi.org/10.1158/1557-3265.AACRIASLC18-A36
Published: 01 September 2018
View articletitled, Abstract A36: Establishment of patient-derived xenograft models of lung adenocarcinoma with two different EGFR mutations, L858R and exon19 deletion
Journal Articles

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model

Free
Akihiro Nishiyama, Tadaaki Yamada, Kenji Kita, Rong Wang, Sachiko Arai, Koji Fukuda, Azusa Tanimoto, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Noritaka Furuya, Takayoshi Kinoshita, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2357–2369.
https://doi.org/10.1158/1078-0432.CCR-17-1623
Published: 14 May 2018
View articletitled, Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Open the PDF for Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model in another window
Includes: Supplementary data
Journal Articles

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer

Free
Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3139–3149.
https://doi.org/10.1158/1078-0432.CCR-16-2271
Published: 14 June 2017
View articletitled, Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Open the PDF for Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells

Free
Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR7.
https://doi.org/10.1158/1078-0432.MECHRES-PR7
Published: 04 March 2013
View articletitled, Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells
Open the PDF for Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells in another window
Journal Articles

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Free
Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Kenji Kita, Takayuki Nakagawa, Shigeki Nanjo, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (13): 3592–3602.
https://doi.org/10.1158/1078-0432.CCR-11-2972
Published: 01 July 2012
View articletitled, Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Open the PDF for Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

Free
Wei Wang, Qi Li, Shinji Takeuchi, Tadaaki Yamada, Hitomi Koizumi, Takahiro Nakamura, Kunio Matsumoto, Naofumi Mukaida, Yasuhiko Nishioka, Saburo Sone, Takayuki Nakagawa, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1663–1671.
https://doi.org/10.1158/1078-0432.CCR-11-1171
Published: 14 March 2012
View articletitled, Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Open the PDF for Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells

Free
Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Kenji Kita, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B21.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B21
Published: 01 February 2012
View articletitled, Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells
Open the PDF for Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells in another window
Journal Articles

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Free
Ivan S. Donev, Wei Wang, Tadaaki Yamada, Qi Li, Shinji Takeuchi, Kunio Matsumoto, Takao Yamori, Yasuhiko Nishioka, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2260–2269.
https://doi.org/10.1158/1078-0432.CCR-10-1993
Published: 14 April 2011
View articletitled, Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Open the PDF for Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer in another window
Includes: Supplementary data